Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.61 |
| ▸ | RELA | Q04206 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | GRK5 | P34947 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18605713 | 0.97 | MAP4K4 (0.59) | MAP4K4NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL15614090 | 0.97 | MAP4K4 (0.59) | MAP4K4NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL12443219 | 0.87 | MAP4K4 (0.66) | MAP4K4NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL4859450 | 0.83 | MAP4K4 (0.56) | MAP4K4NPC1RAB9ASMN1; SMN2NFKB1 | |
| Biphenyl SCHEMBL27673401 | 0.81 | HSP90AA1 (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL28881812 | 0.81 | NPC1 (0.54) | MAP4K4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1256178 | 0.79 | MAPT (0.70) | MAP4K4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL23249762 | 0.78 | MAP4K4 (0.59) | MAP4K4MAPTLMNAHSD17B10CYP3A4 | |
| SCHEMBL10917995 | 0.77 | MAPT (0.55) | MAP4K4NPC1RAB9ASMN1; SMN2MAPT | |
| Biphenyl SCHEMBL11844992 | 0.77 | HSP90AA1 (0.65) | MAP4K4NPC1RAB9ASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4225006-A2 | ORGANIC LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2023-08-09 | — | — | EP | disclosed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7595322-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1605752-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | CYTOKINETICS, INCORPORATED | 2007-04-05 | — | — | US | disclosed |
| EP-1605752-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004086865-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-3965101-A | CNS STIMULANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | MAP4K4 1000/4885NPC1 4826/4885RAB9A 2843/4885 |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | MAP4K4 4033/4885NPC1 548/4885RAB9A 1619/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | MAP4K4 2652/4885NPC1 1272/4885RAB9A 143/4885 |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | MYLK2, MYH2, MYH14 | MAP4K4 551/4885NPC1 4811/4885RAB9A 2948/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | MAP4K4 4049/4885NPC1 1470/4885RAB9A 1971/4885 |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | CHEK1, PLK1, CHEK2 | MAP4K4 181/4885NPC1 4354/4885RAB9A 3613/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | MAP4K4 867/4885NPC1 1592/4885RAB9A 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.